认知定义的阿尔茨海默氏症痴呆症子组具有明显的缩模式
Paul K Crane1, Colin Groot2,3, Rik Ossenkoppele2,3
1Department of Medicine, University of Washington, Seattle, Washington, USA.
Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 14, 2023
概括
结构性MRI扫描显示了阿尔茨海默病 (AD) 亚组中明显的脑缩模式. 这些成像发现与特定的认知障碍相关,有助于分组识别.
科学领域:
- 神经成像是一种神经成像.
- 神经学 神经学
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 阿尔茨海默病 (AD) 的异质性带来了诊断挑战.
- 了解AD认知亚型中的结构磁共振成像 (MRI) 变异至关重要.
研究的目的:
- 在基于认知障碍的AD亚组中识别特定的MRI特征.
- 将认知定义的子组与成像定义的子组进行比较.
主要方法:
- 利用了来自阿尔茨海默病神经成像计划 (ADNI) 的数据.
- 包括584名阿尔茨海默病患者 (461名粉素阳性) 和118名粉素阴性对照.
- 使用基于voxel的形态测量来评估灰色物质体积 (GMV) 的差异.
主要成果:
- 在AD-Memory小组中,表现出中叶缩.
- 在AD-Language小组中,左半球转基因病毒减少和显著不对称.
- 在AD-Executive和AD-Visuospatial小组中,分别显示前部和后部GMV的减少.
- 认知定义的AD-Memory子组与成像定义的边缘主导组保持一致.
结论:
- 显著的MRI模式与阿尔茨海默病中的特定认知缺陷相关.
- 这些发现支持基于神经成像和认知概况的AD亚型的分化.
相关概念视频
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
Dementia
115
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
115
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195


